To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death. This 1:1 propensity score matched cohort study from 647 public health clinics in Malaysia included all patients with COVID-19 with positive tests aged 18 years and older, who were eligible for nirmatrelvir-ritonavir treatment within 5 days of illness from July 14, 2022, to November 14, 2022. The exposed group was patients with COVID-19 initiated with nirmatrelvir-ritonavir treatment, whereas those not initiated with the drug served as the control group. Data was analyzed from July 14, 2022 to December 31, 2022. A total of 20,966 COVID-19 high-risk outpatients (n = 10,483 for nirmatrelvir-ritonavir group and n = 10,483 for control group) were included in the study. Nirmatrelvir-ritonavir treatment was associated with a 36% reduction (adjusted hazard ratio 0.64 [95% CI 0.43, 0.94]) in hospitalization compared with those not given the drug. There was a single ICU admission for the control group and one death each was reported in the nirmatrelvir-ritonavir and control group, respectively. Nirmatrelvir-ritonavir treatment was associated with reduced hospitalization in high-risk patients with COVID-19 even in highly vaccinated populations.
Post COVID-19 condition is an important public health problem as we emerge from the COVID-19 pandemic. In this prospective cohort study, we aimed to determine the prevalence of this condition and assess its associated factors and impact on health-related quality of life in a population setting in Malaysia. Study was conducted from April to June 2022 when the Omicron variant predominated. All individuals testing positive for SARS-CoV-2 infection (RT-PCR, RTK-Ag) were invited for participation. Study questionnaires were delivered via the MySejahtera platform (mobile application). From the total of 44,386 participants who provided responses up to 3-months interval, 1,510 participants (3.4%) fulfilled the post COVID-19 condition criteria. Majority of the affected participants (83.8%, n = 1,265) experienced either cough, fatigue or forgetfulness–the three most common symptoms. Being females, having existing comorbidities, presence of symptoms and requiring hospital admission during the acute illness were associated with higher likelihoods of developing the post COVID-19 condition at 3-months interval. Amongst the 1,510 individuals, one in five had limitations in performing their usual daily activities while at least one in three expressed that their work was affected. Understanding this condition better is essential to guide strategic and responsive plans of action, which may require coordinated multidisciplinary interventions.
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir within 5 days of a COVID-19 illness in order to avert hospitalization within a 30-day period in the Malaysia setting; (ii) determine how variations in pricing and hospitalization rates will affect the cost-effectiveness of nirmatrelvir/ritonavir. Methods The 30-day hospitalization related to COVID-19 was determined using 1 to 1 propensity score-matched real-world data in Malaysia from 14 July 2022 to 14 November 2022. To determine the total per-person costs related to COVID-19, we added the cost of drug (nirmatrelvir/ritonavir or control), clinic visits and inpatient care. Incremental cost-effectiveness ratio (ICER) per hospitalization averted was calculated. Results Our cohort included 31,487 patients. The rate of hospitalization within 30 days was found to be 0.35% for the group treated with nirmatrelvir/ritonavir, and 0.52% for the control group. The nirmatrelvir/ritonavir group cost an additional MYR 1,625.72 (USD 358.88) per patient. This treatment also resulted in a reduction of 0.17% risk for hospitalization, which corresponded to an ICER of MYR 946,801.26 (USD 209,006.90) per hospitalization averted. Conclusion In Malaysia, where vaccination rates were high, nirmatrelvir/ritonavir has been shown to be beneficial in the outpatient treatment of adults with COVID-19 who have risk factors; however, it was only marginally cost effective against hospitalization for healthy adults during the Omicron period.
Introduction: The coronavirus disease 2019 (COVID-19) has disrupted most of the standard face-to-face consultations and has indirectly necessitated adoption of digitalisation into the healthcare services. We aim to assess the clinical applications and challenges of digital health during the pandemic. Methodology: We conducted a systematic search by using three databases including Pubmed, Cochrane and Scopus from December 2019 to May 2021. Included studies examined any elements of digital health in all aspects of healthcare during COVID-19 pandemic, published in English language and available in full-text articles. Independent reviewers assessed the search results, extracted data and quality of the included studies. Results: A total of 47 studies out of initial 282 search results met the inclusion criteria and were extracted for information on types of digital health, clinical applications and challenges. Digital health were used for paediatric populations (n=3), single gender populations only (n=4) whilst the remaining for mixed gender adult populations (n=40). The common clinical applications of digital were for orthopaedics and cardiovascular medicine fields. Majority of the studies showed effective application of telemedicine during COVID-19 for consultations between remote client and healthcare provider, remote monitoring of client health or diagnostic data by provider and also transmission of medical data to healthcare provider. However, challenges to digital health identified included patient factors, staffing factors, digital barriers and economic barriers. Discussion / Conclusion: Digital health is an effective solution for managing healthcare services. However, the challenges need to be addressed appropriately to promote more utilisation of digital health during this challenging time. Disclaimer: Abstract text might vary slightly from what is displayed in the e-poster.
Introduction: The coronavirus disease 2019 (COVID-19) has disrupted most of the standard face-to-face consultations and has indirectly necessitated adoption of digitalisation into the healthcare services. We aim to assess the clinical applications and challenges of digital health during the pandemic. Methodology: We conducted a systematic search by using three databases including Pubmed, Cochrane and Scopus from December 2019 to May 2021. Included studies examined any elements of digital health in all aspects of healthcare during COVID-19 pandemic, published in English language and available in full-text articles. Independent reviewers assessed the search results, extracted data and quality of the included studies. Results: A total of 47 studies out of initial 282 search results met the inclusion criteria and were extracted for information on types of digital health, clinical applications and challenges. Digital health were used for paediatric populations (n=3), single gender populations only (n=4) whilst the remaining for mixed gender adult populations (n=40). The common clinical applications of digital were for orthopaedics and cardiovascular medicine fields. Majority of the studies showed effective application of telemedicine during COVID-19 for consultations between remote client and healthcare provider, remote monitoring of client health or diagnostic data by provider and also transmission of medical data to healthcare provider. However, challenges to digital health identified included patient factors, staffing factors, digital barriers and economic barriers. Discussion / Conclusion: Digital health is an effective solution for managing healthcare services. However, the challenges need to be addressed appropriately to promote more utilisation of digital health during this challenging time. Disclaimer: Abstract text might vary slightly from what is displayed in the e-poster.